Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2281-2289

  Capolunghi, Federica ^a   Rosado, Maria M ^a   Cascioli, Simona ^a   Girolami, Elia ^a   Bordasco, Silvia ^a   Vivarelli, Marina ^a   Ruggiero, Barbara ^a   Cortis, Elisabetta ^a   Insalaco, Antonella ^a   Fantò, Nicola ^b   Gallo, Grazia ^b   Nucera, Eleonora ^b   Loiarro, Maria ^c,d   Sette, Claudio ^c,d   De santis, Rita ^b   Carsetti, Rita ^a   Ruggiero, Vito ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Sigma Tau SpA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Santa Lucia IRCCS Foundation   (Italy)

Author keywords

Autoantibodies; Cell signalling; Cytosine phosphate guanine; Memory B cells; MyD88; SLE; ST2825; Toll like receptor 9

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; MYELOID DIFFERENTIATION FACTOR 88 INHIBITOR; PROTEIN INHIBITOR; ST 2825; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODY FORMATION; ANTIBODY-PRODUCING CELLS; AUTOANTIBODIES; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CPG ISLANDS; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MYELOID DIFFERENTIATION FACTOR 88; SPIRO COMPOUNDS; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 78249238729     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq226     Document Type: Article

References (30)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
2. Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther 2008;10: 218-26.
3. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349: 1526-33.
4. Yurasov S, Wardemann H, Hammersen J et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-11.
5. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008;20: 632-8.
6. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity 2007;26:205-13.
7. Mietzner B, Tsuiji M, Scheid J et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008;105:9727-32.
8. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 2006;203:393-400.
9. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann NY Acad Sci 2008;1143:21-34.
10. Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19:11-23.
11. Nickerson KM, Christensen SR, Shupe J et al. TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010;184:1840-8.
12. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-61.
13. Isnardi I, Ng YS, Srdanovic I et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008;29:746-57.
14. Nakano S, Morimoto S, Suzuki J et al. Role of pathogenic auto-antibody production by toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 2008;47:145-9.
15. Capolunghi F, Cascioli S, Giorda E. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 2008;180: 800-8.
16. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004;197:179-91.
17. Loiarro M, Sette C, Gallo G et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-kB. J Biol Chem 2005;280:15809-14.
18. Loiarro M, Capolunghi F, Gallo G et al. Inhibition of MyD88 dimerization and of recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007;82: 801-10.
19. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-202.
20. Tan EM, Feltkamp TE, Smolen JS et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
21. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-32.
22. Levesque M. Translational mini-review on B-cell directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009;157:198-208.
23. Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005; 140:205-12.
24. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol 2009; 5:348-51.
25. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibodies specificity and have opposing inflammatory and regulatory roles in murine model of lupus. Immunity 2006;25:417-28.
26. Kim W-U, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 2009;8:204-8.
27. Van Tassell BW, Seropian IM, Toldo S et al. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol 2010; 55:385-90.
28. Blyszczuk P, Kania G, Dieterle T et al. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res 2009;105:912-20.
29. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008;223:271-83.
30. Loiarro M, Ruggiero V, Sette C. Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm. Advance Access published April 8, 2010, doi: 10.1155/2010/674363.